Opinion

Video

Expert Perspectives on the Latest TROPION-Lung01 Data

Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.

This is a video synopsis/ summary of an OncLive Insights® featuring Edgardo S. Santos, MD, FACP, FCCP.

Santos highlighted data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan for patients with previously treated non–small cell lung cancer (NSCLC). Compared with docetaxel, datopotamab deruxtecan improved median progression-free survival to 4.4 from 3.7 months (HR, 0.75; P=.004). Subgroup analyses showed benefit across most patient subsets, though docetaxel remained superior for squamous histology. Despite the progression-free survival gain, an increased risk of interstitial lung disease occurred with datopotamab deruxtecan (7 grade 5 cases). Nonetheless, results of this early trial suggest datopotamab deruxtecan has activity in NSCLC post–platinum-based chemotherapy.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.